Abstracts tagged "Abatacept"

Abstract Number: 504 • 2014 ACR/ARHP Annual Meeting
Abatacept after Rituximab in Rheumatoid Arthritis. a Pan-European Collaboration of RA Registries
Axel Finckh¹, David Neto², M. Victoria Hernández³, Florenzo Iannone⁴, Elisabeth Lie⁵, Helena Canhao⁶, K Pavelka⁷, Carl Turesson⁸, Xavier Mariette⁹, Merete Lund Hetland¹⁰ and Jacques Gottenberg¹¹, ¹Rheumatology, Geneva University Hospital, Geneva, Switzerland, ²University of Geneva, Geneva, Switzerland, ³Arthritis Unit. Rheumatology Department, Hospital Clínic of Barcelona, Barcelona, Spain, ⁴Reumatologia Universita e Policlinico di Bari, Bari, Italy, ⁵Department of Rheumatology and Inflammation Research, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden, ⁶Rheumatology Research Unit, Instituto de Medicina Molecular, Universidade de Lisboa, Lisbon, Portugal, ⁷Institute of Rheumatology, Prague, Czech Republic, ⁸Section of Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden, ⁹rheumatology, Université Paris-Sud, Le Kremlin Bicêtre, France, ¹⁰DANBIO, Center for Rheumatology and Spine Diseases, Glostrup Univ Hospital, Glostrup, Denmark, ¹¹Rheumatology, Strasbourg University Hospital, Strasbourg, France
Background/Purpose Some observations have suggested that the effectiveness of abatacept (ABA) may be decreased in rheumatoid arthritis (RA) patients (pts) who previously failed rituximab (RTX).(1)…
Abstract Number: 1457 • 2013 ACR/ARHP Annual Meeting
Inhibitory Effect Of Abatacept On Joint Damage In Rheumatoid Arthritis Patients With Or Without Concomitant Methotrexate: A Retrospective Multicenter Analysis Of 12 Months Of Abatacept Treatment In Routine Clinical Practice
Isao Matsushita¹, Hiraku Motomura¹, Eiko Seki¹ and Tomoatsu Kimura², ¹Department of Orthopaedic Surgery, Faculty of Medicine, University of Toyama, Toyama, Japan, ²Department of rthopaedic Surgery, Faculty of Medicine, University of Toyama, Toyama, Japan
Background/Purpose: Abatacept is approved for use with or without methotrexate (MTX). The purpose of this study was to clarify the inhibitory effect of abatacept on…
Abstract Number: 424 • 2013 ACR/ARHP Annual Meeting
2-Year Results From The Ample (Abatacept versus Adalimumab Comparison in Biologic-Naïve RA Patients with Background Methotrexate) Trial: Changes In Patient-Reported Outcomes In Response To Subcutaneous Abatacept Or Adalimumab In Rheumatoid Arthritis
Roy Fleischmann¹, ME Weinblatt², M Schiff³, D Khanna⁴, MA Maldonado⁵, A Nadkarni⁶ and Daniel Furst⁷, ¹University of Texas Southwestern Medical Center, Dallas, TX, ²Rheumatology & Immunology, Brigham & Women's Hospital, Boston, MA, ³University of Colorado, Denver, CO, ⁴University of Michigan, Ann Arbor, MI, ⁵Bristol-Myers Squibb, Princeton, NJ, ⁶Bristol-Myers Squibb, Plainsboro, NJ, ⁷University of California at Los Angeles, Los Angeles, CA
Background/Purpose: RA is a debilitating disease that can impact health-related quality of life (HRQoL) through impairment of activity, loss of independence and reduced work productivity.…
Abstract Number: 1465 • 2013 ACR/ARHP Annual Meeting
Adherence To The Recommended Dosing Regimen Of Abatacept In The Real-World Setting In The Action Study: Is There a Dose-Creep In Overweight Patients?
H Nüßlein¹, R Alten², M Galeazzi³, H M Lorenz⁴, D Boumpas⁵, M T Nurmohamed⁶, W G Bensen⁷, Gerd Burmester⁸, H-H Peter⁹, F Rainer¹⁰, K Pavelka¹¹, M Chartier¹², C Poncet¹³, C Rauch¹⁴ and M Le Bars¹⁵, ¹University Erlangen, Nürnberg, Germany, ²Schlosspark-Klinik, University Medicine Berlin, Berlin, Germany, ³University of Siena, Siena, Italy, ⁴University Hospital Heidelberg, Heidelberg, Germany, ⁵Panepistimio Kritis, Rethymnon, Greece, ⁶VU University Medical Center/Jan van Breeman Research Institute, Amsterdam, Netherlands, ⁷St. Joseph's Hospital/McMaster University, Hamilton, ON, Canada, ⁸Charité-Universitätsmedizin, Berlin, Germany, ⁹University of Freiburg, Freiburg, Germany, ¹⁰Hospital Barmherzige Brueder, Graz, Austria, ¹¹Institute of Rheumatology, Prague, Czech Republic, ¹²Chiltern International, Neuilly, France, ¹³Docs International, Nanterre, France, ¹⁴Bristol-Myers Squibb, Munich, Germany, ¹⁵Bristol-Myers Squibb, Rueil-Malmaison, France
Background/Purpose: Reduced efficacy for achieving DAS28 30 kg/m2,1 which in theory could induce dose increases to maintain efficacy. Here we explore adherence to abatacept over…
Abstract Number: 1442 • 2013 ACR/ARHP Annual Meeting
Three-Year Drug Survival and Effectiveness Of Abatacept and Tocilizumab In Patients with Rheumatoid Arthritis Treated In Routine Care. Results From The Nationwide Danish Danbio Registry
HCB Leffers^1,2, Mikkel Østergaard³, Bente Glintborg⁴, Niels Steen Krogh⁵, Ulrik Tarp⁶, Tove Lorenzen⁷, Annette Hansen⁸, Lene Dreyer⁹ and Merete L. Hetland³, ¹DANBIO, On behalf of Depts of Rheumatology, North, South, Central, Zealand and Capital Region, Glostrup, Denmark, ²Department of Rheumatology, Frederiksberg Hospital, Frderiksberg, Denmark, ³Copenhagen University Hospital Glostrup, Copenhagen, Denmark, ⁴Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Glostrup Hospital, Glostrup, Denmark, ⁵ZiteLab ApS, Copenhagen, Denmark, ⁶Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, ⁷Department of Rheumatology, Region Hospital Silkeborg, Silkeborg, Denmark, ⁸Department of Rheumatology, Gentofte University Hospital, Copenhagen, Denmark, ⁹Internal Medicine - Rheumatology Section, Copenhagen University Hospital at Gentofte, Copenhagen, Denmark
Background/Purpose: Treatment with abatacept and tocilizumab has been shown to be efficacious in rheumatoid arthritis (RA) patients refractory to tumor necrosis factor inhibitor (TNFi). However,…
Abstract Number: 1448 • 2013 ACR/ARHP Annual Meeting
Drug Retention Rates Of Biologic Monotherapies For Patients With Rheumatoid Arthritis In Daily Clinical Practice; Using Multicenter Registry In Japan
Hiroyuki Matsubara¹, Toshihisa Kojima², Masatoshi Hayashi³ and Naoki Ishiguro⁴, ¹Rheumatology, Handa Municipal Hospital, Handa, Japan, ²Orthopedic Surgery and Rheumatology, Nagoya University Hospital, Nagoya, Japan, ³Departments of Orthopedic surgery and Rheumatology, Nagano Red Cross Hospital, Nagano, Japan, ⁴Orthopaedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine, Nagoya, Japan
Background/Purpose: In general, drug retention rate reflects the effectiveness and tolerability of the drug. In Japan, six biological agents have been approved for the treatment…
Abstract Number: 1455 • 2013 ACR/ARHP Annual Meeting
Comparison Of Serum Matrix Metalloproteinase-3 Levels In Rheumatoid Arthritis After Treatment With Adalimumub Or Abatacept For 24 Weeks
Yosuke Hattori¹, Atsushi Kaneko¹, Daihei Kida², Hisato Ishikawa³, Toshihisa Kojima⁴ and Naoki Ishiguro⁵, ¹Orthopedic Surgery and Rheumatology, Nagoya Medical Center, Nagoya, Japan, ²Department of Rheumatology and Orthopedic Surgery, Nagoya Medical Center, Nagoya, Japan, ³Nagoya Medical Center, nagano, Japan, ⁴Orthopedic Surgery and Rheumatology, Nagoya University Hospital, Nagoya, Japan, ⁵Orthopaedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine, Nagoya, Japan
Background/Purpose : MMP-3 is an enzyme produced by synoviocytes, and is a marker of synovitis that gives a more direct indication of actual joint destruction…
Abstract Number: 1385 • 2013 ACR/ARHP Annual Meeting
A Study Of Natural Killer Cell Subfractions In Abatacept Therapy For Rheumatoid Arthritis
Masao Sato¹, Masao Takemura², Ryuki Shinohe¹, Yasuko Yamamoto³ and Kuniaki Saito³, ¹Orthopaedic Surgery, Gifu University, Gifu, Japan, ²Informative Clinical Medicine, Gifu University, Gifu, Japan, ³Human Health Science, Kyoto University, Kyoto, Japan
Background/Purpose: Inflammatory cytokines and cell-mediated immunity function of mainly lymphocytes are complicatedly involved in disease onset of rheumatoid arthritis (RA). Recently, together with biologicals such…
Abstract Number: 884 • 2013 ACR/ARHP Annual Meeting
Treatment Of Lupus Nephritis With Abatacept Plus Low-Dose Pulse Cyclophosphamide Followed By Azathioprine (the Euro-Lupus Regimen): Twenty-Four Week Data From a Double-Blind Controlled Trial
David Wofsy¹, Anca Askanase², Patricia C. Cagnoli³, W. Winn Chatham⁴, Gabriel Contreras⁵, Maria Dall'era⁶, Mary Anne Dooley⁷, Hilda Fragoso-Loyo⁸, David R. Karp⁹, Meenakshi Jolly¹⁰, Kenneth Kalunian¹¹, Diane L. Kamen¹², Iris Lee¹³, Marc C. Levesque¹⁴, S. Sam Lim¹⁵, Meggan Mackay¹⁶, Cesar Ramos-Remus¹⁷, Brad H. Rovin¹⁸, Tammy O. Utset¹⁹, Swamy Venuturupalli²⁰, Robert Winchester²¹, Linna Ding²², Wendy Gao²², Lynette Keyes-Elstein²³ and Patti Tosta²⁴, ¹Rheumatology/Immunology, University of California San Francisco and NIAID Autoimmunity Centers of Excellence, San Francisco, CA, ²NYU School of Medicine, New York, NY, ³Int Med/Div of Rheum, University of Michigan Health, Ann Arbor, MI, ⁴University of Alabama at Birmingham, Birmingham, AL, ⁵University of Miami, Miami, FL, ⁶Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, ⁷University of North Carolina at Chapel Hill, Chapel Hill, NC, ⁸Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico, Mexico, ⁹Rheumatic Diseases Division, UT Southwestern Medical Center, Dallas, TX, ¹⁰Rheumatology, Rush University Medical Center, Chicago, IL, ¹¹UCSD School of Medicine, La Jolla, CA, ¹²Department of Medicine, Division of Rheumatology, Medical University of South Carolina, Charleston, SC, ¹³Nephrology, Temple University, Philadelphia, PA, ¹⁴Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ¹⁵Emory University School of Medicine, Division of Rheumatology, Atlanta, GA, ¹⁶Autoimmune & Musculoskeletal Disease, Feinstein Institute for Medical Research, Manhasset, NY, ¹⁷Unidad de Investigacion en Enfermedades Cronico-Degenerativas, Guadalajara, Mexico, ¹⁸Division of Nephrology, Ohio State University Medical Center, Columbus, OH, ¹⁹Rheumatology, University of Chicago Medical Center, Chicago, IL, ²⁰Cedars-Sinai Medical Center, West Hollywood, CA, ²¹Dept of Medicine & Pathology, Columbia University, New York, NY, ²²NIAID, Bethesda, MD, ²³Rho Federal Systems, Inc., Chapel Hill, NC, ²⁴Immune Tolerance Network, San Francisco, CA
Background/Purpose: Studies in murine models for SLE have shown that CTLA4Ig can ameliorate murine lupus nephritis. Moreover, the combination of CTLA4Ig plus intravenous cyclophosphamide (IVC)…
Abstract Number: 795 • 2013 ACR/ARHP Annual Meeting
Second TNF-Inhibitor Or Alternative Biologic In Juvenile Idiopathic Arthritis (JIA) Patients Failing a First TNF-Inhibitor
Kirsten Minden¹, Klaus Tenbrock², Gerd Horneff³ and Hans-Iko Huppertz⁴, ¹Children’s University Hospital Charite/German Rheumatism Research Centre Berlin, Berlin, Germany, ²University Aachen, Aachen, Germany, ³Department of Pediatrics, Asklepios Klinik Sankt Augustin, Sankt Augustin, Germany, ⁴Prof. Hess Childrens Hospital, Bremen, Germany
Background/Purpose: Patients with incomplete response to initial anti-TNF treatment often are switched to other biologic treatments. However, little is known about the efficacy of switching…
Abstract Number: 720 • 2013 ACR/ARHP Annual Meeting
Abatacept Efficacy Is Overruled By IL-7 In TSLP-Primed Myeloid Dendritic cell driven T Cell Activation From Rheumatoid Arthritis Patients
F.M. Moret¹, T.R.D.J. Radstake², J.W.J. Bijlsma¹, F.P.J.G. Lafeber³ and J.a.G. van Roon⁴, ¹Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ²Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ³Rheumatology & Clinical Immunology, UMC Utrecht, Utrecht, Netherlands, ⁴Rheumatology & Clinical Immunology/Lab Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands
Background/Purpose: Abatacept is an effective treatment for a subset of rheumatoid arthritis (RA) patients, interfering in the interaction between antigen-presenting cells and T cells preventing…
Abstract Number: 723 • 2013 ACR/ARHP Annual Meeting
Abatacept Is Highly Effective At Inhibiting T Cell Priming and Induces a Unique Transcriptional Profile In CD4⁺t Cells
Agapitos Patakas¹, Rui-Ru Ji², William Weir³, Sean Connolly², Steven G. Nadler², James M. Brewer⁴, Iain B. McInnes⁴ and Paul Garside⁴, ¹Institute of Infection, Immunology and Inflammation, University of Glasgow, Glasgow, United Kingdom, ²Department of Immunology and Inflammation, Bristol Myers Squibb Co. Research and Development, Princeton, NJ, ³Institute of Biodiversity, Animal Health and Comparative Medicine, University of Glasgow, Glasgow, United Kingdom, ⁴Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom
Background/Purpose: Absence of co-stimulation in the presence of TCR-stimulation has been proposed to induce tolerance via deletion or anergy. Abatacept is a CTLA-4-Ig molecule that…
Abstract Number: 495 • 2013 ACR/ARHP Annual Meeting
The Impact Of Inadequate Response To Prior Biologic Agents On Abatacept Drug Retention In Rheumatoid Arthritis Patients. A Pan-European Analysis Of RA Registries
Axel Finckh¹, Florenzo Iannone², Juan Gomez Reino³, David Neto⁴, Elisabeth Lie⁵, Piet van Riel⁶, Merete Lund Hetland⁷, Karel Pavelka⁸, Carl Turesson⁹, Xavier Mariette¹⁰ and Jacques-Eric Gottenberg¹¹, ¹Department of Medical Specialities, University of Geneva, Geneva, Switzerland, ²D.I.M.I.M.P, Rheumatology Unit - University of Bari, Bari, Italy, ³Rheumatology Department, Hospital Clínico de Santiago, Santiago de Compostela, Spain, ⁴Rheumatology, University of Geneva, Geneva, Switzerland, ⁵Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁶Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ⁷Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, The Danish Rheumatologic Database (DANBIO), Glostrup Hospital., Copenhagen, Denmark, ⁸Department of Clinical and Experimental Rheumatology, Charles University, Prague, Czech Republic, ⁹Lund University, Malmö, Sweden, ¹⁰Paris-Sud University, Paris, France, ¹¹Division of Rheumatology, University Hospital of Strasbourg, Strasbourg, France
Background/Purpose: In rheumatoid arthritis (RA), abatacept (ABA) may be used in biologic naïve patients (pts) or after failure to an anti-TNF or other biologic agents…
Abstract Number: 499 • 2013 ACR/ARHP Annual Meeting
Efficacy and Safety Of Infliximab Or Adalimumab Vs Abatacept In Patients With Rheumatoid Arthritis and An Inadequate Response To Methotrexate: Attest-Ample Network Randomized Trial
Robin Christensen¹, Simon Tarp¹, Daniel Furst², Lars E. Kristensen³ and Henning Bliddal⁴, ¹Musculoskeletal Statistics Unit, The Parker Institute, Department of Rheumatology, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Denmark, ²David Geffen School of Medicine, University of California, Los Angeles, CA, ³Rheumatology, Department of Clinical Sciences, Lund, Section of Rheumatology, Lund University, Lund, Sweden, ⁴Department of Rheumatology, The Parker Institute, Department of Rheumatology, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Denmark
Background/Purpose: Using combined data from the ATTEST [1] and AMPLE [2] study comparing infliximab and adalimumab with abatacept in patients with rheumatoid arthritis (RA), we…
Abstract Number: 465 • 2013 ACR/ARHP Annual Meeting
Higher Titer Of Anti-Citrullinated Protein Antibodies In Biologic-Naïve Rheumatoid Arthritis Patients Are Candidate Biomarkers To Predict Sensitivity Leading To Clinical Remission With Abatacept; Data From The Abroad Study
Takao Fujii¹, Masahiro Sekiguchi², Kiyoshi Matsui², Masayasu Kitano², Motomu Hashimoto³, Koichiro Ohmura⁴, Aihiro Yamamoto⁵, Hideko Nakahara⁶, Keiji Maeda⁷, Akira Yokota⁸, Kenji Miki⁹, Naoki Shimmyo¹⁰, Takanori Kuroiwa¹¹, Kosaku Murakami¹², Yoshio Ozaki¹³, Kenshi Higami¹⁴, Ichiro Yoshii¹⁵, Yuji Nozaki¹⁶, Takashi Ikawa¹⁷, Satoshi Morita¹⁸, Yutaka Kawahito⁵, Norihiro Nishimoto¹⁹, Tsuneyo Mimori⁴ and Hajime Sano², ¹Department of the Control for Rheumatic Diseases, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ²Division of Rheumatology, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya-city, Japan, ³The Control for Rheumatic Diseases, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ⁴Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ⁵Department of Inflammation and Immunology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan, ⁶Division of Allergy, Rheumatology and Connective Tissue Diseases, Department of Internal Medicine, NTT West Osaka Hospital, Osaka, Japan, ⁷Allergy, Rheumatology and Connective Tissue Diseases, Department of Internal Medicine, NTT West Osaka Hospital, Osaka, Japan, ⁸Yokota Clinic for Rheumatology, Osaka, Japan, ⁹Department of Orthopaedic Surgery, Amagasaki Central Hospital, Amagasaki, Japan, ¹⁰Kashiba Asahigaoka Hospital, Kashiba, Japan, ¹¹Department of Rheumatology, Yukioka Hospital, Osaka, Japan, ¹²Dept of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ¹³Kansai Medical University Hirakata Hospital, Hirakata, Japan, ¹⁴Department of Rheumatology, Higami Hospital, Nara, Japan, ¹⁵Department of Orthopaedic Surgery, Yoshii Hospital, Shimanto, Japan, ¹⁶Kinki University Faculty of Medicine, Sayama, Japan, ¹⁷Osaka Rehabilitation Hospital, Hannan, Japan, ¹⁸Graduate School of Medicine & Medical Center, Department of Biostatistics and Epidemiology, Yokohama City University, Kanagawa, Japan, ¹⁹Osaka Rheumatology Clinic, Osaka, Japan
Background/Purpose: Biomarkers to predict each rheumatoid arthritis (RA) patient’s sensitivity for biologic disease modifying anti-rheumatic diseases, especially for the only T cell modulator abatacept (ABT),…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].